Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Development

Novartis trims 20% of its research programs

by Lisa M. Jarvis
November 3, 2018 | A version of this story appeared in Volume 96, Issue 44

 

Novartis has shed 90 programs from its drug pipeline as part of a portfolio review meant to make its drug engine more agile. First reported by Bloomberg, the culling amounts to 20% of Novartis’s overall drug pipeline. According to a Novartis spokesperson, the projects jettisoned range from discovery stage to early clinical development; 80% have yet to reach human clinical trials. The big pharma firm earlier licensed three anti-infective drug candidates to Boston Pharmaceuticals and is now considering what others make sense for external development.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.